Department of Pulmonary Medicine, Huadong Hospital, Shanghai 200040, China.
Mediators Inflamm. 2011;2011:560194. doi: 10.1155/2011/560194. Epub 2011 Jul 13.
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), continue to be a major cause of morbidity and mortality in critically ill patients. The present therapeutic strategies for ALI/ARDS including supportive care, pharmacological treatments, and ventilator support are still controversial. More scientists are focusing on therapies involving stem cells, which have self-renewing capabilities and differentiate into multiple cell lineages, and, genomics therapy which has the potential to upregulate expression of anti-inflammatory mediators. Recently, the combination of cell and gene therapy which has been demonstrated to provide additive benefit has opened up a new chapter in therapeutic strategy and provides a basis for the development of an innovative approach for the prevention and treatment of ALI/ARDS.
急性肺损伤（ALI）及其更严重的形式，急性呼吸窘迫综合征（ARDS），仍然是危重病患者发病率和死亡率的主要原因。目前ALI/ARDS 的治疗策略包括支持性护理、药物治疗和呼吸机支持，但仍存在争议。更多的科学家正在关注涉及干细胞的治疗方法，这些细胞具有自我更新能力并分化为多个细胞谱系，以及基因组治疗，它有可能上调抗炎介质的表达。最近，细胞和基因治疗的联合已被证明具有附加益处，为治疗策略开辟了新篇章，并为 ALI/ARDS 的预防和治疗提供了创新方法的发展基础。
